Editas Medicine, Inc. (EDIT)
After hours:
| Previous close | 5.89 |
| Open | 5.89 |
| Bid | 5.57 x 300 |
| Ask | 5.64 x 700 |
| Day's range | 5.59 - 5.93 |
| 52-week range | 4.91 - 11.91 |
| Volume | |
| Avg. volume | 2,012,998 |
| Market cap | 462.178M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.07 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.36 |
GuruFocus.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
GlobeNewswireEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
Simply Wall St.Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest quarterly report and things are not looking great...
